Biotech Archives - Page 668 of 733

2 minute read

Nuvalent To Present Preliminary Phase 1 Data From ARROS-1 Clinical Trial Of NVL-520 At 34th EORTC-NCI-AACR Symposium October 26-28 And Announces Pipeline Updates

September 7, 8:18 AM

CAMBRIDGE, Mass., Sept. 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase

NUVL

1 minute read

Pfizer Gets FDA Breakthrough Therapy Designation For GBS Vaccine Candidate

By Ragothaman Srinivasan

September 7, 8:17 AM

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE: PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy.

PFE

6 minute read

Praxis Precision Medicines Announces Plan To Start PRAX-222 EMBRAVE Clinical Study

By Bill Haddad

September 7, 7:34 AM

BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central

PRAX

1 minute read

This Small Biotech Company Touts Promising Data For Alzheimer’s Candidate

By Vandana Singh

September 7, 7:08 AM

BioVie Inc (NASDAQ:BIVI) announced topline results from an investigator-Sponsored Phase 2 trial of NE3107 for Alzheimer’s Disease (AD). The company says…

BIVI

1 minute read

Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels

By Vandana Singh

September 7, 7:00 AM

Zealand Pharma A/S (NASDAQ:ZEAL) has entered into a global license and development agreement with Novo Nordisk A/S (NYSE:NVO) to commercialize Zegalogue (dasiglucagon) for…

NVO

1 minute read

Immunovant Announces Two New Development Programs For Batoclimab

By Bill Haddad

September 7, 6:31 AM

Plan to initiate a Pivotal Phase 2b trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 20221 with initial results from open-label period 1 expected in the first half of

IMVT

1 minute read

BioVie Announces Topline Results From Investigator-Sponsored Exploratory Biomarker And Imaging Trial Of NE3107 For Treatment Of Alzheimer’s Disease; Says ‘Vast majority of patients saw significant improvements in the Global Rating of Change’

By Bill Haddad

September 7, 6:03 AM

Vast majority of patients saw significant improvements in the Global Rating of Change (overall impression of patient's daily abilities) with NE3107 treatment (p<0.0001 to p<0.05). NE3107 is

BIVI

1 minute read

Equillium Buys Inflammatory Bowel Disease Player In All-Stock Deal

By Vandana Singh

September 7, 5:58 AM

Equillium Inc (NASDAQ:EQ) has agreed to acquire Metacrine Inc (NASDAQ:MTCR) in an all-stock transaction. The transaction is anticipated to add $33 million…

1 minute read

Rhythm Secures European Commission Marketing Authorization For Genetic Disease Candidate

By Ragothaman Srinivasan

September 6, 5:11 PM

The European Commission (EC) has expanded the marketing authorization for Rhythm’s (NASDAQ: RYTM) lead drug product IMCIVREE (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients 6 years of age an

RYTM